about
Current imaging techniques in rheumatology: MRI, scintigraphy and PETAdrenal incidentaloma imaging - the first steps in therapeutic managementN-acetylaspartate, choline, myoinositol, glutamine and glutamate (glx) concentration changes in proton MR spectroscopy (1H MRS) in patients with mild cognitive impairment (MCI).Initial study of radiological and clinical efficacy radioembolization using 188Re-human serum albumin (HSA) microspheres in patients with progressive, unresectable primary or secondary liver cancers.Can scintimammography with (99m)Tc-MIBI identify multifocal and multicentric primary breast cancer?Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.Recurrent hypoglycaemia in a type 2 diabetes patient - diagnostic difficulties.Intermittent Pneumatic Compression Enhances Formation of Edema Tissue Fluid Channels in Lymphedema of Lower Limbs.Radiosynovectomy in rheumatic diseasesAdrenal (131)I-6β-iodomethylnorcholesterol scintigraphy in choosing the side for adrenalectomy in bilateral adrenal tumors with subclinical hypercortisolemiaThe comparison of efficacy of different imaging techniques (conventional radiography, ultrasonography, magnetic resonance) in assessment of wrist joints and metacarpophalangeal joints in patients with psoriatic arthritis.Diagnostic imaging approach to gastro-entero-pancreatic carcinomas of neuroendocrine origin - single NET center experience in Poland.A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease managementMediastinal paragangliomas related to SDHx gene mutations.Evaluation of Head and Neck Paragangliomas by Computed Tomography in Patients with Pheochromocytoma-Paraganglioma Syndromes.Disseminated Pancreatic Neuroendocrine Neoplasm (NEN) with an Uncommon Localisation in the Central Nervous System. A Case ReportENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas.Colorectal neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors.Long-term efficacy of (90)Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms.The clinical utility of circulating neuroendocrine gene transcript analysis in well-differentiated paragangliomas and pheochromocytomas.Gastroduodenal neuroendocrine neoplasms, including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).Scintigraphic imaging of breast cancer: a review.Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotideFGF23 Producing Mesenchymal Tumor.Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.Three-dimensional personalized dosimetry for (188)Re liver selective internal radiation therapy based on quantitative post-treatment SPECT studies.Comparison of functional imaging and standard CT in evaluation of disease extent in patients with tumours showing neuroendocrine features.Molecular strategies in the management of bronchopulmonary and thymic neuroendocrine neoplasms.[Radioisotope therapy with somatostatin analogues in neuroendocrine tumours (case report)].Diagnostic imaging of carcinoid metastases to the abdomen and pelvis.Uptake of Tc-99m MIBI related to tumour size and type.Diagnostic accuracy of mammography and scintimammography in detection of primary breast cancer related size of the tumour.Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours).The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors.The use of 67Ga scintigraphy in patients with sarcoidosis.PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy.Usefulness of Somatostatin Receptor Scintigraphy (Tc-[HYNIC, Tyr3]-Octreotide) and 123I-Metaiodobenzylguanidine Scintigraphy in Patients with SDHx Gene-Related Pheochromocytomas and Paragangliomas Detected by Computed Tomography.GROWTH RATE OF PARAGANGLIOMAS RELATED TO GERMLINE MUTATIONS OF THE SDHX GENES.Prediction of deterioration of mild cognitive impairment with CT and SPECT.
P50
Q26823321-2CA7FA4E-C482-4291-98F1-05135211B328Q26862481-A5DB4EA8-FC97-4930-B4D8-79430B34757BQ34029600-C4F58574-9E35-4848-8588-E83E34839623Q34062165-00B4D7C6-1243-4E39-9AC3-79821A22E1A0Q34441672-88E8F97F-B944-4E0B-84E3-A3254518CA49Q34618199-55D1E475-26C0-45A3-B718-EBCC946A461CQ35755395-A4A418D0-021D-4155-8B2C-D46ED1A4FDDFQ35821709-231FF361-788C-41E7-8A1C-265A7E42563DQ36085135-C7040642-2F7B-40BE-B791-429967C97513Q36095819-917A18D7-C8E4-4783-87EE-771296B1F643Q36680293-25FD5E32-5453-488D-9D19-B1C38A5BB3A4Q37026631-724A0DC4-A38F-44AE-B35E-E369D161DD1CQ37302087-0F49E99D-B65D-4A49-86AC-17B18D718939Q37352164-3F812349-CFCC-4795-BA1D-C1C4252CA76BQ37403954-E1FC5BFB-F80D-4978-ABB1-32D4E4B684E4Q37691470-E5D1B548-512A-4570-8D95-841CEE8664F1Q38686994-AEF823AD-D202-4203-97A8-AD11970AD0F9Q38765743-0EDAFABA-2155-4AD4-A71F-17C204C0751DQ38769465-BB008222-8E59-42AF-BA36-507BAB1D090BQ38870046-88BD32F4-8547-4EC3-8D05-34CD0E24A7A3Q39134724-1C07858C-8F56-4111-B8C3-D81238729DCFQ40186992-D62849B9-12F9-443D-A6B1-A9BEF19754FFQ40885090-5D8F7A9A-954D-4237-8E7E-5111023C5EFFQ41691693-F557D1E6-25E8-4BA8-ACCA-114488145686Q41967673-253FBA12-CF89-460B-A461-CEB4E161F9BAQ43260540-7231B2AE-F4A2-4BF1-9A1A-030FC7C60B84Q44391883-EB02C351-EE7C-4600-9769-91765BBA62B8Q44644529-0FB2ABBF-32A8-4F6D-8099-2FA1CA5F06F4Q45360690-F82A135B-3B56-4216-9523-9E0DEE2050AFQ46840921-324FC8A6-D9A8-4DC4-B2F9-325DE1856C24Q46990966-F977E955-BA74-46CE-83FA-817B1EC410A4Q47309339-144209F1-6DD7-462C-A19B-B8007908A27EQ47402649-DD46E888-E997-4158-A211-22484AA9F426Q47574245-62EFB5BF-7503-4491-AAD3-29A6CA6C8427Q47589004-0D3572D3-469F-4E69-8BB8-17CAC07689C4Q50107400-9E735B9C-0DA4-4FA4-B58E-08AB3DF34453Q50421758-131A76A2-69B2-44E2-8989-C2D2A94ED8D1Q50945568-B1BA4380-EC52-461B-9B6E-D51B466D7268Q51012320-70A067D2-DFD6-41BB-8842-EBE7DCAAF7FAQ51101890-BB894532-93E7-41C5-88F9-012E7FE5C8B1
P50
description
Pools onderzoeker
@nl
polski naukowiec
@pl
researcher ORCID ID = 0000-0001-5147-4167
@en
name
Jaroslaw Cwikla
@ast
Jaroslaw Cwikla
@en
Jaroslaw Cwikla
@es
Jaroslaw Cwikla
@nl
Jarosław Ćwikła
@ca
Jarosław Ćwikła
@cs
Jarosław Ćwikła
@gl
Jarosław Ćwikła
@hr
Jarosław Ćwikła
@hsb
Jarosław Ćwikła
@it
type
label
Jaroslaw Cwikla
@ast
Jaroslaw Cwikla
@en
Jaroslaw Cwikla
@es
Jaroslaw Cwikla
@nl
Jarosław Ćwikła
@ca
Jarosław Ćwikła
@cs
Jarosław Ćwikła
@gl
Jarosław Ćwikła
@hr
Jarosław Ćwikła
@hsb
Jarosław Ćwikła
@it
altLabel
Jaroslaw B. Cwikla
@en
Jarosław Bogdan Ćwikła
@pl
prefLabel
Jaroslaw Cwikla
@ast
Jaroslaw Cwikla
@en
Jaroslaw Cwikla
@es
Jaroslaw Cwikla
@nl
Jarosław Ćwikła
@ca
Jarosław Ćwikła
@cs
Jarosław Ćwikła
@gl
Jarosław Ćwikła
@hr
Jarosław Ćwikła
@hsb
Jarosław Ćwikła
@it
P106
P1412
P1559
Jarosław Ćwikła
@pl
P21
P27
P31
P3124
P496
0000-0001-5147-4167